Companion Guidance For Combo Products Rule Clears Up Some Gray Areas
This article was originally published in The Silver Sheet
Executive Summary
The draft guidance provides real-world application, examples and detailed instructions for compliance with agency good manufacturing practice rules for drug delivery devices and other drug/device, drug/biological and drug/device/biological products.
You may also be interested in...
Industry Seeks More Clarity Following Combo Product GMP Final Rule
FDA’s final regulation outlines which manufacturing system requirements apply to products that have drug, device and/or biologic components. An industry coalition says key details need to be filled in by FDA with guidance.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.